AMN Healthcare Services
AMNNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $37.81 Prior regular-session close from the quote source.
- $37.19–$38.55 Regular-session low and high so far today.
- 491.2K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 4 projected Projected for 2027-02-04 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $14.97–$49.62 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own AMN if AMN is a post-pandemic healthcare staffing recovery bet: the business has real network value and cash generation, but the burden is proving that hospital labor demand and bill-rate spreads have stabilized rather than structurally.
AMN price history
Loading recent earnings…
Investment thesis
What must happen next
Hospitals continue to need outsourced access to qualified clinicians, so AMN's broad professional network remains a necessary capacity tool rather than a pandemic-only service.WeakeningMateriality: High
Profile description says AMN has one of the nation's broadest networks of highly-qualified healthcare professionals. If this holds, revenue can stabilize and recover; if it breaks, AMN's core demand pool is structurally smaller.
Watch: Large hospital systems permanently replace travel clinicians with internal float pools and lower contract-labor targets.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Profile description says AMN has one of the nation's broadest networks of highly-qualified healthcare professionals.
Open source ↗AMN can defend its pay-bill spread because scale, compliance, credentialing, and client service matter more than simply matching clinicians at the lowest price.WeakeningMateriality: High
GAAP annual gross profit remained substantial at $774.058 million in FY2025. If AMN keeps pricing power, revenue recovery can translate into profit; if spreads compress, growth may not create value.
Watch: Hospital procurement departments force lower bill rates across vendor panels and managed-service-provider renewals.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit remained substantial at $774.058 million in FY2025.
Open source ↗Management can resize AMN's cost base after the demand reset so the platform returns to operating profitability without needing another pandemic-level staffing spike.HoldingMateriality: Medium
GAAP annual operating loss improved from $102.673 million in FY2024 to $55.472 million in FY2025. This determines whether AMN is a normalized earnings recovery or a structurally overbuilt platform.
Watch: Corporate, technology, and compliance costs prove too fixed for the lower revenue base.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss improved from $102.673 million in FY2024 to $55.472 million in FY2025.
Open source ↗AMN's asset-light staffing model and working-capital discipline allow it to generate operating cash through the downturn, giving the company time to repair profitability.StrengtheningMateriality: Medium
GAAP annual operating cash flow was positive at $269.457 million in FY2025 despite a GAAP net loss. Positive cash flow reduces financing risk and gives management flexibility even while GAAP earnings are weak.
Watch: A demand recovery consumes working capital faster than collections, turning growth into a cash drain.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was positive at $269.457 million in FY2025 despite a GAAP net loss.
Open source ↗AMN can use cash generation and asset-light operations to keep balance-sheet risk manageable while waiting for staffing demand to normalize.HoldingMateriality: Medium
Total liabilities declined from $2.093 billion at FY2023 year-end to $1.709 billion at FY2024 year-end and $1.452 billion at FY2025 year-end. If leverage pressure stays contained, shareholders can participate in recovery; if not, debt holders or refinancing terms capture the upside.
Watch: A prolonged staffing slump reduces cash flow before remaining debt and lease obligations are reduced.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities declined from $2.093 billion at FY2023 year-end to $1.709 billion at FY2024 year-end and $1.452 billion at FY2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Hospitals continue to need outsourced access to qualified clinicians, so AMN's broad professional network remains a necessary capacity tool rather than a pandemic-only service. If this holds, revenue can stabilize and recover; if it breaks, AMN's core demand pool is structurally smaller.
AMN can defend its pay-bill spread because scale, compliance, credentialing, and client service matter more than simply matching clinicians at the lowest price. If AMN keeps pricing power, revenue recovery can translate into profit; if spreads compress, growth may not create value.
Management can resize AMN's cost base after the demand reset so the platform returns to operating profitability without needing another pandemic-level staffing spike. This determines whether AMN is a normalized earnings recovery or a structurally overbuilt platform.
AMN's asset-light staffing model and working-capital discipline allow it to generate operating cash through the downturn, giving the company time to repair profitability. Positive cash flow reduces financing risk and gives management flexibility even while GAAP earnings are weak.
AMN can use cash generation and asset-light operations to keep balance-sheet risk manageable while waiting for staffing demand to normalize. If leverage pressure stays contained, shareholders can participate in recovery; if not, debt holders or refinancing terms capture the upside.
All standing thesis claims
Original report summary
AMN is a post-pandemic healthcare staffing recovery bet: the business has real network value and cash generation, but the burden is proving that hospital labor demand and bill-rate spreads have stabilized rather than structurally.
Bull case and bear case
Bull case and bear case for AMN Healthcare Services
Where the evidence on AMN Healthcare Services disagrees: Mixed on the latest evidence (Nov 12, 2026). Of its 5 thesis points, 1 strengthening, 2 holding and 2 weakening.
Bull case: what the evidence supports
Management can resize AMN's cost base after the demand reset so the platform returns to operating profitability without needing another pandemic-level staffing spike.
AMN's asset-light staffing model and working-capital discipline allow it to generate operating cash through the downturn, giving the company time to repair profitability.
AMN can use cash generation and asset-light operations to keep balance-sheet risk manageable while waiting for staffing demand to normalize.
Bear case: what the evidence questions
Hospitals continue to need outsourced access to qualified clinicians, so AMN's broad professional network remains a necessary capacity tool rather than a pandemic-only service.
AMN can defend its pay-bill spread because scale, compliance, credentialing, and client service matter more than simply matching clinicians at the lowest price.
Thesis-Break Engine
Thesis-break watch · AMN Healthcare Services
No break has crossed AMN Healthcare Services’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
AMN Healthcare Services filed an SEC 8-K on 2026-11-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
AMN Healthcare Services filed an SEC 8-K on 2026-05-04: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large hospital systems permanently replace travel clinicians with internal float pools and lower contract-labor targets.
- Hospital procurement departments force lower bill rates across vendor panels and managed-service-provider renewals.
- Corporate, technology, and compliance costs prove too fixed for the lower revenue base.
- A demand recovery consumes working capital faster than collections, turning growth into a cash drain.
- A prolonged staffing slump reduces cash flow before remaining debt and lease obligations are reduced.
AMN news
Loading headlines…
Financial statements
AMN income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AMN: quick answers
- When does AMN Healthcare Services (AMN) report earnings next?
- AMN Healthcare Services's next results are projected for February 4, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
- What is AMN's short interest?
- As of October 30, 2026, 4.3M AMN shares were sold short, 11.1% of its shares outstanding, up 11.5% from the count before. At the stock's average daily volume that is 3.9 days to cover. FINRA publishes the count twice a month. AMN short interest history
- Have members of Congress traded AMN?
- 19 trades in AMN have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed AMN trade
